- Subjects who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.
- Subjects with documented clinical diagnosis of diabetic macular edema (DME) with
proliferative or non proliferative diabetic retinopathy.
- Subjects, who according to the clinical assessment of the investigator, may benefit
from anti-VEGF therapy including those subjects who were participating in the A5751013
study and who, in the investigator's opinion, may benefit from continued pegaptanib
- Eyes with prior scatter (panretinal) photocoagulation within 4 months prior to
baseline or anticipated scatter (panretinal) photocoagulation within the next 6
- Presence of any abnormality that is likely to confound assessment of visual acuity
improvement in eyes in which macular edema resolves, or improves, such as
non-perfusion for >1 disc area involving the foveal avascular zone (FAZ - involving 2
or more quadrants centered around the foveal avascular zone), epiretinal membrane
associated with signs of contraction and/or significant opacification (i.e. striae
within 1 disc diameter of the foveal center), or presence of chorioretinal atrophy
involving the center of the macula.
- Vitreomacular traction determined clinically and/or by optical coherence tomography
(OCT), which, in the investigator's opinion, contributes to the macular edema (or
causes associated foveal detachment), and would preclude improvement with pegaptanib
- Any other cause of macular edema such as vitreous extension, or entrapment to anterior
segment wound, or any retinal vein occlusion involving the macula.